NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against
leucine-rich repeat containing 15 (LRRC15) linked, via the protease-cleavable valine-citrulline
linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE),
with potential antineoplastic activity. Upon administration of samrotamab vedotin,
the samrotamab moiety targets and binds to LRRC15 expressed on cancer-associated fibroblasts
(CAFs) and tumor cells. Upon binding and internalization, MMAE is released after proteolytic
cleavage. MMAE targets and binds to tubulin, and inhibits microtubule polymerization.
This results in G2/M phase cell cycle arrest and apoptosis in LRRC15-expressing CAFs
and tumor cells. LRRC15, a type I membrane protein and a member of the LRR superfamily,
is highly expressed on CAFs in the tumor microenvironment (TME) within some tumor
stroma and on tumor cells in certain tumors.;
Currated CISMeF NLP mapping